Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Sanofi Pasteur head David Loew has been at the heart of the company's bids to develop vaccines for COVID-19 but has decided to accept a different challenge instead and take the helm at Ipsen.
Executives On The Move: Exits At Allergan And Sanofi, And Wave Life Sciences Fills Newly Created Position
Artax Biopharma, focusing on autoimmune diseases, selects Sanofi Genzyme R&D SVP as its new CMO, and Allergan chief information officer accepts same post at Merck spin off Organon & Co. Also, genetic medicines company Wave Life Sciences fills newly created position of SVP of therapeutics discovery.
Executives On The Move: TG Therapeutics Brings Aboard Pioneering Academic Scientist for Its C-Suite, Roche Decides On A Research Exec And Ascendis Announces A New Global Officer
TG Therapeutics, developing treatments for B-cell malignancies, adds an authority in lymphoma as CSO, and Roche hires a Broad Institute exec to head up Genentech’s research and early development. Plus, Ascendis Pharma, with programs in endocrinology/oncology, picks a global chief commercial officer.
Executives On The Move: New Choices For Finance Spots At Merz Aesthetics, Spruce Biosciences And Lodo Therapeutics
New CFOs are announced at three companies: MerzPharma Group’s Merz Aesthetics; Spruce Biosciences, a firm focusing on treatments for rare endocrine disorders; and Lodo Therapeutics, which is developing novel therapeutics for undruggable targets.
Sol Barer, founder and former CEO of Celgene, has been appointed chair of Cerecor; he is already chair of Teva, Centrexion Therapeutics and NexImmune. Also, PTC Therapeutics announces promotions and ProBioGen gets a new CEO.
Executives On The Move: BioMarin Pharma Selects Technology And Operations Head, Celgene CFO Makes A Switch And Sangamo Welcomes CBO
BioMarin Pharmaceutical selects a new CTO and EVP of Manufacturing and Ops, and Swiss oncology biotech ADC Therapeutics hires a former Celgene CFO. Plus, genomic medicines firm Sangamo Therapeutics welcomes a CBO to oversee commercialization strategies.
Pharma manufacturer Juphar Gulf Pharmaceutical decides on a new CEO to drive operational transformation, and the CCO at Ipsen moves to CEO post at cancer therapy firm Immunomedics to execute company growth. In addition, protein therapeutics business Five Prime Therapeutics gains oncology industry leader as CEO.
Executives On The Move: Sandoz Chooses New Country Head, A Bayer Exec Departs For Idogen, And Heat Biologics Forms Covid-19 Board
Sandoz International chooses a new country head for Japan, and a Bayer medical director departs to become CMO of Swedish biotech Idogen. Also, Heat Biologics forms a Covid-19 advisory board to propel its Covid-19 vaccine and diagnostic programs.
Executives On The Move: I-Mab Brings On An Amgen Communications Exec And SciTech Picks A CMO, Along With A Promotion At Urovant Sciences
I-Mab Biopharma, a Chinese firm focusing on biologics for cancer and immune diseases, brings on an Amgen exec as global head, corporate communications, and SciTech Development, with its proprietary nano-delivery system, adds a new CMO. Plus, urologic therapies company Urovant Sciences promotes a director to CEO.
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
Executives On The Move: Global Aesthetics Head Exits Allergan for Merz, C-Level Commercial Changes at Flexion And Karyopharm
Merz Pharma Group’s Merz Aesthetics welcomes former Allergan exec as new chief scientific officer. Meanwhile, a chief commercial officer is appointed at Flexion Therapeutics, developer of treatments for musculoskeletal conditions, and at Karyopharm Therapeutics, an oncology-focused pharma.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.